The use of 5-HT3 receptor antagonists in various rheumatic diseases - A clue to the mechanism of action of these agents in fibromyalgia?

Scandinavian Journal of Rheumatology, Supplement

Volumn 29, Issue 113, 2000, Pages 66-71

  Stratz, T ^a   Muller W ^a  

^a Hochrhein Institut   (Germany)

Author keywords

5 HT3 receptor antagonists; Cervical pain; Low back pain; Periarthritis; Rheumatoid arthritis; Treatment; Tropisetron

Indexed keywords

CORTICOSTEROID; NEUROKININ; SEROTONIN; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; SUBSTANCE P; TROPISETRON; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR;

CATECHOLAMINE RELEASE; CHRONIC PAIN; CONFERENCE PAPER; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN; INFLAMMATION; LOW BACK PAIN; OSTEOARTHRITIS; PAIN; PERIARTHRITIS; PRIORITY JOURNAL; RHEUMATIC DISEASE; ARTICLE; CHRONIC DISEASE; FIBROMYALGIA; PAIN ASSESSMENT; PATHOPHYSIOLOGY; PHYSIOLOGY; PILOT STUDY; RHEUMATOID ARTHRITIS;

ARTHRITIS, RHEUMATOID; CHRONIC DISEASE; FIBROMYALGIA; HUMANS; LOW BACK PAIN; OSTEOARTHRITIS; PAIN; PAIN MEASUREMENT; PILOT PROJECTS; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT3; RHEUMATIC DISEASES; SEROTONIN ANTAGONISTS;

EID: 0033641378     PISSN: 03013847     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (18)

1. Anichini M, Cesaretti S, Lepori M, Maddali Bongi S, Maresca M, Zoppi M. Substance P in the serum of patients with rheumatoid arthritis. Rev Rhum Engl 1997;64:18-21.
2. Arnalich F, de Miguel E, Perez-Ayala C, Martinez M, Vazquez JJ, Gijon-Banos J, Hernanz A. Ncuropeptides and interleukin-6 in human joint inflammation relationship between intraarticular substance P and interleukin-6 concentration. Neurosci Lett 1994;170:251-4.
3. Blunk J, Osiander G, Nischik M, Schmelz M. Pain and inflammatory hyperalgesia induced by intradermal injections of human platelets and leukocytes. Europ J Pain 1999;3:227-59.
4. Chahl LA, Szolcsanyi J, Lembeck F. Antidromic vasodilatation and neurogenic inflammation. Akademiai Kiado, Budapest 1984.
5. Covas MJ, Pinto LA, Pereira Da Silva JA, Victorino RM. Effects of the neuropeptide, substance P, on lymphocyte proliferation in rheumatoid arthritis. J Int Med Res 1995:431-8.
6. Färber L, Stratz Th, Brückle W, Späth M, Pongratz D, Lautenschläger J, Kötter I, Zöller B, Peter H-H, Neeck G, Welzel D, Müller W. Usefulness of the 5-HT3-receptor antagonist Tropisetron in primary fibromyalgia. Annals of the Rheumatic Diseases, EULAR-Kongress Scotland 1999;Nr. 570:p. 140.
7. Färber L, Stratz Th, Müller W. New aspects for the medical treatment of results of a double-blind, randomized, placebocontrolled multi-centre trial evaluating the efficacy and tolerability of the 5-HT3-antagonist tropisetron in primary fibromyalgie. Zschr Rheumatol 1998;57 Supplement 1:30.
8. Heavy DD, Barnes V-F, Orwin J, Braun MJ. Inhibition of 5-HAT-induced axon reflex flares by MDL 72422. Br J Clin Pharmacol 1986;21:558.
9. Hernanz A, De Miguel E, Romera N, Perez-Ayala C, Gijon J, Arnalich F. Calcitonin gene-related peptide II, substance P and vasoactive intestinal peptide in plasma and synovial fluid from patients with inflammatory joint disease. Br J Rheumtol 1993;32:31-5.
10. Levine JD, Clark R, Devor M, Helms C, Moskowitz MA, Basbaum AI. Intraneuronal substance P contributes to the severity of experimental arthritis. Science 1984;226:547-9.
11. Locatelli L, Sacerdote P, Mantegazza P, Panerai AE. Effect of ibuprofen and diclofenac on the chemotaxis induced by substance P and transforming growth factor-beta on human monocyte and polymorphonuclear cells. Int J Immunopharmacol 1993;15:833-8.
12. Lotz M, Carson DA, Vaughan JH. Substance P activation of rheumatoid synoviocytes: neural pathway in pathogenesis of arthritis. Science 1987;235:893-5.
13. Matucci-Cerinic M, Lombardi A, Leoncini G, Pignone A, Sacerdoti L, Spillantini MG, Partsch G. Neutral endopeptidase (3.4.24.11) in plasma and synovial fluid of patients with rheumatoid arthritis. A marker of disease activity or a regulator of pain and inflammation? Rheumatol Int 1993;13:1-4.
14. Menkes CJ, Renoux M, Laoussadi S, Mauborgne A, Bruxelle J, Cesselin F. Substance P levels in the synovium fluid from patients with rheumatoid arthritis and osteoarthritis. J Rheumatol 1993;20:714-7.
15. Späth M, Stratz Th, Schmalisch P, Fischer P, Haslinger A, Schwarz M, Müller W, Pongratz D. Substance P in skeletal muscle of patients with fibromyalgia syndrome. J Musculoskel Pain 1998;6 Suppl 2.
16. Stratz Th, Samborski W, Hrycaj P, Pap Th, Mackiewicz S, Mennet P, Müller W. Die Scrotoninkonzentration im Serum bei Patienten mit generalisierter Tendomyopathie (Fibromyalgie) und chronischer Polyarthritis. Med Klinik 1993;88:458-62.
17. Vaeroy H, Helle R, Forre O, Kass E, Terenius L. Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain 1988;32:21-6.
18. Wilcox GL. Excitatory neutrotransmitters and pain. In: Bond MR., Charlton JE., Woolf CJ. eds. Proceedings of the Vth World Congress on Pain. Pain Research and Clinical Management. Elsevier, Amsterdam 1991 Vol. 4, 97-117.